CN107207509B - 作为沉默调节蛋白调节剂的取代的桥环脲类似物 - Google Patents

作为沉默调节蛋白调节剂的取代的桥环脲类似物 Download PDF

Info

Publication number
CN107207509B
CN107207509B CN201580073897.3A CN201580073897A CN107207509B CN 107207509 B CN107207509 B CN 107207509B CN 201580073897 A CN201580073897 A CN 201580073897A CN 107207509 B CN107207509 B CN 107207509B
Authority
CN
China
Prior art keywords
branched
straight
compound
sirtuin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580073897.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107207509A (zh
Inventor
J.L.埃利斯
K.A.埃文斯
R.M.福克斯
W.H.米勒
M.A.塞费尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of CN107207509A publication Critical patent/CN107207509A/zh
Application granted granted Critical
Publication of CN107207509B publication Critical patent/CN107207509B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580073897.3A 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥环脲类似物 Expired - Fee Related CN107207509B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19
US62/081,916 2014-11-19
PCT/IB2015/058978 WO2016079710A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (2)

Publication Number Publication Date
CN107207509A CN107207509A (zh) 2017-09-26
CN107207509B true CN107207509B (zh) 2020-04-21

Family

ID=54705247

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201580073897.3A Expired - Fee Related CN107207509B (zh) 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN201580073782.4A Pending CN107207521A (zh) 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥连脲类似物
CN201580073769.9A Pending CN107207520A (zh) 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN201580073311.3A Pending CN107108627A (zh) 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥环脲类似物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201580073782.4A Pending CN107207521A (zh) 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥连脲类似物
CN201580073769.9A Pending CN107207520A (zh) 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN201580073311.3A Pending CN107108627A (zh) 2014-11-19 2015-11-19 作为沉默调节蛋白调节剂的取代的桥环脲类似物

Country Status (21)

Country Link
US (4) US10072011B2 (https=)
EP (4) EP3221316A1 (https=)
JP (4) JP2017534664A (https=)
KR (4) KR20170083135A (https=)
CN (4) CN107207509B (https=)
AU (4) AU2015348942B2 (https=)
BR (4) BR112017010602A2 (https=)
CA (4) CA2968027A1 (https=)
CL (1) CL2017001275A1 (https=)
CO (1) CO2017004994A2 (https=)
CR (1) CR20170209A (https=)
DO (1) DOP2017000123A (https=)
EA (1) EA201791074A1 (https=)
ES (1) ES2823748T3 (https=)
IL (1) IL252252A0 (https=)
MX (1) MX2017006658A (https=)
PE (1) PE20171257A1 (https=)
PH (1) PH12017500913A1 (https=)
RU (3) RU2017120855A (https=)
SG (1) SG11201703824QA (https=)
WO (4) WO2016079709A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653782B2 (en) * 2014-11-25 2020-05-19 Nortwestern University Retroviral particles expressing Sirt1 embedded within PPCN
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
KR20220056223A (ko) * 2019-09-02 2022-05-04 메르크 파텐트 게엠베하 유기 전계발광 디바이스용 재료
MX2022006087A (es) * 2019-11-19 2022-08-11 Lupin Ltd Proceso de preparación de compuestos de cromano.
HRP20251132T1 (hr) * 2020-01-17 2025-11-21 Lupin Limited Postupci, procesi i međuproizvodi za pripremu spojeva kromana
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺
WO2025194094A1 (en) * 2024-03-15 2025-09-18 The Regents Of The University Of Michigan Small molecule modulators of sirt5 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
WO2011059839A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
EP2790701A1 (en) * 2011-12-12 2014-10-22 SMB Innovation Novel heterocyclic compounds useful in sirtuin binding and modulation
CN105392788B (zh) * 2013-05-13 2018-10-23 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的桥连脲类似物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
WO2011059839A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators

Also Published As

Publication number Publication date
JP2017534664A (ja) 2017-11-24
CA2968029A1 (en) 2016-05-26
US20170355705A1 (en) 2017-12-14
BR112017010602A2 (pt) 2017-12-26
CN107207520A (zh) 2017-09-26
MX2017006658A (es) 2018-01-15
EP3221317A1 (en) 2017-09-27
CN107207521A (zh) 2017-09-26
WO2016079709A1 (en) 2016-05-26
EP3221316A1 (en) 2017-09-27
IL252252A0 (en) 2017-07-31
US20180319810A1 (en) 2018-11-08
EP3221322A1 (en) 2017-09-27
CO2017004994A2 (es) 2017-09-20
RU2017120855A (ru) 2018-12-19
EP3220918A1 (en) 2017-09-27
AU2015348941A1 (en) 2017-06-01
KR20170087907A (ko) 2017-07-31
KR20170083134A (ko) 2017-07-17
JP2017534665A (ja) 2017-11-24
CN107207509A (zh) 2017-09-26
US20170362234A1 (en) 2017-12-21
JP6806679B2 (ja) 2021-01-06
EA201791074A1 (ru) 2017-10-31
ES2823748T3 (es) 2021-05-10
CL2017001275A1 (es) 2017-12-15
CR20170209A (es) 2017-07-17
JP2017534662A (ja) 2017-11-24
PE20171257A1 (es) 2017-08-28
US20190048016A1 (en) 2019-02-14
AU2015348944A1 (en) 2017-06-01
CA2968032A1 (en) 2016-05-26
EP3221317B1 (en) 2020-07-22
BR112017010595A2 (pt) 2018-01-02
KR20170083133A (ko) 2017-07-17
JP2017534663A (ja) 2017-11-24
BR112017010599A2 (pt) 2017-12-26
WO2016079712A1 (en) 2016-05-26
AU2015348943A1 (en) 2017-06-01
AU2015348942A1 (en) 2017-06-01
DOP2017000123A (es) 2017-08-15
BR112017010601A2 (pt) 2017-12-26
WO2016079710A1 (en) 2016-05-26
CN107108627A (zh) 2017-08-29
US10072011B2 (en) 2018-09-11
WO2016079711A1 (en) 2016-05-26
RU2017120858A (ru) 2018-12-19
PH12017500913A1 (en) 2017-12-04
CA2968027A1 (en) 2016-05-26
RU2017120857A (ru) 2018-12-19
SG11201703824QA (en) 2017-06-29
CA2968030A1 (en) 2016-05-26
KR20170083135A (ko) 2017-07-17
AU2015348942B2 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
CN107207509B (zh) 作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN104918934B (zh) 3‑取代的吡唑及其作为dlk抑制剂的用途
CN107207496A (zh) 作为沉默调节蛋白调节剂的取代的桥环脲类似物
CN110022875A (zh) 治疗性抑制化合物
CN107074805B (zh) 用于治疗疾病的gls1抑制剂
JP2021502400A (ja) 置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法
TW201733988A (zh) 化學化合物
CN102015705A (zh) 稠合的杂环衍生物及其用途
WO2016081692A2 (en) Substituted bridged urea analogs as sirtuin modulators
HK40006420A (zh) 治疗性抑制化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200421

Termination date: 20211119

CF01 Termination of patent right due to non-payment of annual fee